F9 embryonal carcinoma cells engineered for tamoxifen-dependent Cre-mediated site-directed mutagenesis and doxycycline-inducible gene expression

被引:17
作者
Chiba, H [1 ]
Chambon, P [1 ]
Metzger, D [1 ]
机构
[1] ULP, INSERM, CNRS, Inst Genet & Biol Mol & Cellulaire,Coll France, F-67404 Illkirch Graffenstaden, France
关键词
F9 embryonal carcinoma cells; ligand-inducible Cre recombinase; loxP sites; tamoxifen; tetracycline; tet system; inducible gene expression; mutagenesis; retinoid;
D O I
10.1006/excr.2000.5022
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The study of gene functions in complex genetic environments such as mammalian cells would greatly benefit from systems allowing a tight control of gene expression. The tetracycline-inducible gene expression system and the site-specific Cre/loxP recombination system have gained increasing popularity for conditional expression and gene disruption. To facilitate the analysis of gene functions in a cell autonomous system, we have established an F9 murine embryonal carcinoma cell line, constitutively expressing both the doxycycline-controlled transactivator rtTA and the tamoxifen-dependent Cre recombinase Cre-ERT. The expression of a reporter gene placed under the control of tetracycline operators was induced about 1000-fold by doxycycline, and tamoxifen-induced excision of a loxP-flanked DNA segment occurred in all cells. This genetically engineered cell line, which allows, upon simple ligand addition, sophisticated genetic manipulations, such as sequential inactivation of loxP-flanked genes, and tightly controlled reexpression of their cDNAs, should be a valuable tool for studying mammalian gene functions. (C) 2000 Academic Press.
引用
收藏
页码:334 / 339
页数:6
相关论文
共 36 条
  • [1] Mouse P450RAI (CYP26) expression and retinoic acid-inducible retinoic acid metabolism in F9 cells are regulated by retinoic acid receptor γ and retinoid X receptor α
    Abu-Abed, SS
    Beckett, BR
    Chiba, H
    Chithalen, JV
    Jones, G
    Metzger, D
    Chambon, P
    Petkovich, M
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 1998, 273 (04) : 2409 - 2415
  • [2] CLONING AND EXPRESSION OF THE MOUSE PGK-1 GENE AND THE NUCLEOTIDE-SEQUENCE OF ITS PROMOTER
    ADRA, CN
    BOER, PH
    MCBURNEY, MW
    [J]. GENE, 1987, 60 (01) : 65 - 74
  • [3] LOSS OF RETINOIC ACID RECEPTOR-GAMMA FUNCTION IN F9 CELLS BY GENE DISRUPTION RESULTS IN ABERRANT HOXA-1 EXPRESSION AND DIFFERENTIATION UPON RETINOIC ACID TREATMENT
    BOYLAN, JF
    LOHNES, D
    TANEJA, R
    CHAMBON, P
    GUDAS, LJ
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1993, 90 (20) : 9601 - 9605
  • [4] Spatio-temporally controlled site-specific somatic mutagenesis in the mouse
    Brocard, J
    Warot, X
    Wendling, O
    Messaddeq, N
    Vonesch, JL
    Chambon, P
    Metzger, D
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1997, 94 (26) : 14559 - 14563
  • [5] TKOED - LOX, STOCK AND BARREL
    CHAMBERS, CA
    [J]. BIOESSAYS, 1994, 16 (12) : 865 - 868
  • [6] A decade of molecular biology of retinoic acid receptors
    Chambon, P
    [J]. FASEB JOURNAL, 1996, 10 (09) : 940 - 954
  • [7] Distinct retinoid X receptor retinoic acid receptor heterodimers are differentially involved in the control of expression of retinoid target genes in F9 embryonal carcinoma cells
    Chiba, H
    Clifford, J
    Metzger, D
    Chambon, P
    [J]. MOLECULAR AND CELLULAR BIOLOGY, 1997, 17 (06) : 3013 - 3020
  • [8] Specific and redundant functions of retinoid X receptor retinoic acid receptor heterodimers in differentiation, proliferation, and apoptosis of F9 embryonal carcinoma cells
    Chiba, H
    Clifford, J
    Metzger, D
    Chambon, P
    [J]. JOURNAL OF CELL BIOLOGY, 1997, 139 (03) : 735 - 747
  • [9] RXR alpha-null F9 embryonal carcinoma cells are resistant to the differentiation, anti-proliferative and apoptotic effects of retinoids
    Clifford, J
    Chiba, H
    Sobieszczuk, D
    Metzger, D
    Chambon, P
    [J]. EMBO JOURNAL, 1996, 15 (16) : 4142 - 4155
  • [10] DAMKE H, 1995, METHOD ENZYMOL, V257, P209